pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

venatorx-pharmaceuticals PRESS RELEASE ARCHIVE

Sep 27, 2023

Venatorx Pharmaceuticals to Present at IDWeek 2023

Aug 15, 2023

Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), including Pyelonephritis, in Adults

Aug 14, 2023

Venatorx Pharmaceuticals Highlights Two Recent Publications Indicating Rising Metallo-Beta-Lactamases for Carbapenem-Resistant Enterobacterales in US

Mar 7, 2023

Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman

Dec 20, 2022

Venatorx Pharmaceuticals Announces Organizational Changes

Dec 20, 2022

Venatorx Pharmaceuticals Announces Organizational Changes

Dec 2, 2022

Global Complicated Urinary Tract Infections Market Report to 2032 - Featuring Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals and Allecra Therapeutics Among Others - ResearchAndMarkets.com

Oct 20, 2022

Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022

Oct 11, 2022

Venatorx Pharmaceuticals to Present at IDWeek 2022

Oct 3, 2022

Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract

Apr 4, 2022

Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund

Mar 10, 2022

Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI

Mar 10, 2022

Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial

Dec 2, 2021

Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs

Nov 1, 2021

Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen

Sep 27, 2021

Venatorx Pharmaceuticals to Present Data at IDWeek 2021

Aug 17, 2021

Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam

Jul 28, 2021

Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

Jun 29, 2021

Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science

Jun 28, 2021

Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection

Jun 21, 2021

Venatorx Pharmaceuticals to Present Preclinical Profile of its Hepatitis B Virus Clinical Candidate at the International Liver Congress 2021

Mar 10, 2021

Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate

Jan 28, 2021

Venatorx Pharmaceuticals Names New Head of Regulatory Affairs

Nov 24, 2020

Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC

Oct 21, 2020

Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020

Sep 17, 2020

Venatorx Pharmaceuticals Names William Sargent Senior Vice President, Commercial Strategy

Jul 27, 2020

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

Jun 30, 2020

Venatorx Pharmaceuticals Named ‘Best Places to Work’ Third Year in a Row

Apr 29, 2020

Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections With Limited Treatment Options

Dec 19, 2019

Venatorx Pharmaceuticals Joins the Alliance for Biosecurity

Nov 25, 2019

CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea

Sep 4, 2019

VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

Aug 29, 2019

VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections

Aug 21, 2019

VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio

Aug 6, 2019

VenatoRx Pharmaceuticals named ‘Best Places to Work’ Second Year in a Row

Jul 22, 2019

HHS, DoD, VenatoRx Pharmaceuticals to Co-Develop Novel Antibiotic to Treat Drug-Resistant Infections

Jun 20, 2019

VenatoRx Pharmaceuticals Founders Named Entrepreneur Of The Year 2019 Award Winners in Greater Philadelphia

Jun 17, 2019

VenatoRx Pharmaceuticals to Present at ASM Microbe 2019

Apr 10, 2019

VenatoRx Pharmaceuticals to Present Data for its Injectable and Orally Bioavailable Beta-Lactamase Inhibitor Drug Candidates at ECCMID 2019

Apr 4, 2019

VenatoRx Pharmaceuticals Names Lisa Wittmer, Ph.D. Chief Development Officer

Mar 25, 2019

VenatoRx Pharmaceuticals to Present Orally Bioavailable Broad-Spectrum Beta-Lactamase Inhibitor for Superbugs at ACS National Meeting

Mar 14, 2019

VenatoRx Pharmaceuticals’ Christopher J. Burns, Ph.D. Named CEO of the Year by Life Sciences Pennsylvania

Feb 28, 2019

VenatoRx Pharmaceuticals Awarded NIAID R01 Grant to Uncover Determinants of Gram-Negative Permeability

Feb 6, 2019

VenatoRx Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference

Jan 3, 2019

VenatoRx Pharmaceuticals Joins Antimicrobials Working Group

Oct 2, 2018

VenatoRx Pharmaceuticals to Present in vitro, in vivo and Phase I Data for cefepime/VNRX-5133 at IDWeek 2018

Sep 25, 2018

VenatoRx Pharmaceuticals and Everest Medicines II Limited Announce Exclusive License Agreement for cefepime/VNRX-5133

Aug 9, 2018

VenatoRx Pharmaceuticals named a 2018 Best Places to Work

May 31, 2018

VenatoRx Pharmaceuticals to present at ASM Microbe in the New Agents Discovery Summary Session and Emerging Tech Talks

May 17, 2018

VenatoRx Pharmaceuticals to Present at the 2018 UBS Global Healthcare Conference

Apr 19, 2018

VenatoRx Pharmaceuticals Founders Christopher J. Burns, Ph.D., Luigi Xerri, Ph.D. and Daniel C. Pevear, Ph.D. Named EY Entrepreneur Of The Year 2018 Finalists in the Greater Philadelphia Area

Apr 12, 2018

VenatoRx Pharmaceuticals to Present in vitro and in vivo Data for cefepime/VNRX-5133 at ECCMID 2018

Mar 19, 2018

VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting

Jan 4, 2018

VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens

Jan 3, 2018

VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of Its Lead Antibiotic Program

Jul 27, 2017

VenatoRx Pharmaceuticals Receives $9.4 Million Award from CARB-X to Develop a New Class of Antibiotic to Combat Multi-Drug Resistant Bacteria

Jul 25, 2017

VenatoRx Pharmaceuticals Raises $42 Million Series B

Google Analytics Alternative